What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail
Jointly provided by
Support for this activity has been provided through educational grants from GSK and Pfizer.
Release date: 9/30/2022
Expiration date: 9/30/2023
Estimated time to complete: 1.0 hour
Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative treatment options for patients with MM that has relapsed or become refractory (RRMM) to several lines of therapy.
This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule–based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity.
Amrita Y. Krishnan, MD
Director of Judy and Bernard Briskin Multiple Myeloma Center
Professor of Hematology/Hematopoietic Cell Transplantation
City of Hope Cancer Center
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, New York
This activity has been designed to meet the educational needs of hematologists, oncologists, advanced practice providers, and other health care professionals who treat patients with MM.
Upon completion of this activity, participants should be better able to:
- Distinguish between indicated uses, mechanisms of action, and safety profiles of existing and emerging small-molecule therapies and BCMA–targeted immunotherapy for patients who have relapsed from or are resistant to multiple prior therapies
- Evaluate recent clinical advances in the use of small-molecule therapies and BCMA-targeted immunotherapies in patients with RRMM and their potential implications for clinical practice
- Develop individualized management plans for RRMM patients based on patient-, disease-, and treatment-related factors
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy, the Multiple Myeloma Research Foundation, and RedMedEd. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the ABIM MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring in the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:
Amrita Y. Krishnan, MD, has disclosed the following relevant financial relationships:
Consultant: Adaptive, Artiva, Astra Zeneca, Bristol Myers Squibb, GSK, Janssen, Pfizer, Regeneron, and Sanofi
Speakers Bureau: Amgen, Bristol Myers Squibb, GSK, and Takeda
Scientific Advisory Board: Sutro
Saad Z. Usmani, MD, MBA, FACP, has disclosed the following relevant financial relationships:
Consultant: AbbVie, Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Merck, Oncopeptides, Pharmacyclics, Sanofi, Seattle Genetics, SecuraBio, Skyline DX, Takeda, TeneoBio
Research Funding: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, Skyline DX, and Takeda
Multiple Myeloma Research Foundation (MMRF)
The MMRF planners have disclosed no relevant financial relationships.
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
The RedMedEd planners have disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Purdue University College of Pharmacy, RedMedEd, Multiple Myeloma Research Foundation, GSK, and Pfizer do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Purdue University College of Pharmacy, RedMedEd, Multiple Myeloma Research Foundation, GSK, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Purdue University College of Pharmacy at Pharmacyfirstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or email@example.com.
- iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection
- Internet browsers: Chrome, Firefox, Safari
- A computer with an Internet connection
- Internet browsers (PC): Chrome, Firefox, Microsoft Edge
- Internet browsers (Mac): Chrome, Firefox, Safari
Collection and Use of Information
Personal information (such as name, address, or telephone number) is collected and used only to ensure appropriate continuing education credit is issued to the learner and to inform the learner about additional products or services that may be of interest. Purdue does not sell, trade, or rent personal information to others outside of our own entity.
© 2022. This CME/CE-certified program is held as copyrighted by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. Through this notice, Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.